PF-06459988
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Conditions
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Trial Timeline
Jan 1, 2015 → Mar 1, 2018
NCT ID
NCT02297425About PF-06459988
PF-06459988 is a phase 2 stage product being developed by Pfizer for Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02297425. Target conditions include Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02297425 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC